JP2024536126A - 肝体積を減少させるためのレスメチロム - Google Patents

肝体積を減少させるためのレスメチロム Download PDF

Info

Publication number
JP2024536126A
JP2024536126A JP2024519112A JP2024519112A JP2024536126A JP 2024536126 A JP2024536126 A JP 2024536126A JP 2024519112 A JP2024519112 A JP 2024519112A JP 2024519112 A JP2024519112 A JP 2024519112A JP 2024536126 A JP2024536126 A JP 2024536126A
Authority
JP
Japan
Prior art keywords
resmetirom
subject
prodrug
less
liver
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024519112A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024536126A5 (https=
Inventor
タウプ，レベッカ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Madrigal Pharmaceuticals Inc
Original Assignee
Madrigal Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Madrigal Pharmaceuticals Inc filed Critical Madrigal Pharmaceuticals Inc
Publication of JP2024536126A publication Critical patent/JP2024536126A/ja
Publication of JP2024536126A5 publication Critical patent/JP2024536126A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2024519112A 2021-09-27 2022-09-27 肝体積を減少させるためのレスメチロム Pending JP2024536126A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163248634P 2021-09-27 2021-09-27
US63/248,634 2021-09-27
PCT/US2022/044826 WO2023049491A1 (en) 2021-09-27 2022-09-27 Resmetirom for reducing liver volume

Publications (2)

Publication Number Publication Date
JP2024536126A true JP2024536126A (ja) 2024-10-04
JP2024536126A5 JP2024536126A5 (https=) 2025-10-08

Family

ID=83900064

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024519112A Pending JP2024536126A (ja) 2021-09-27 2022-09-27 肝体積を減少させるためのレスメチロム

Country Status (13)

Country Link
US (2) US20240408102A1 (https=)
EP (2) EP4408428A1 (https=)
JP (1) JP2024536126A (https=)
KR (1) KR20240073926A (https=)
CN (1) CN118251221A (https=)
AR (1) AR127165A1 (https=)
AU (1) AU2022348966A1 (https=)
CA (1) CA3233319A1 (https=)
CL (1) CL2024000886A1 (https=)
IL (1) IL311670A (https=)
MX (1) MX2024003967A (https=)
TW (1) TW202337470A (https=)
WO (1) WO2023049491A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN121443313A (zh) * 2023-06-08 2026-01-30 成都微芯药业有限公司 PPAR全激动剂联合THR-β激动剂在抗代谢相关疾病中的用途
WO2024263714A1 (en) * 2023-06-22 2024-12-26 Madrigal Pharmaceuticals, Inc. BIOMARKERS FOR TREATING LIVER DISORDERS WITH THR-β AGONISTS AND RELATED USES
KR20260000642A (ko) * 2024-06-25 2026-01-05 연세대학교 산학협력단 Usp10 억제제를 유효성분으로 포함하는, 간섬유증 또는 간섬유증 관련 질환의 예방 또는 치료용 조성물

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR092872A1 (es) 2012-09-17 2015-05-06 Madrigal Pharmaceuticals Inc Metodo para sintetizar analogos de la hormona tiroidea y polimorfos de los mismos
CA3111025C (en) * 2018-09-06 2023-10-31 Galmed Research And Development Ltd Combination therapy for the treatment of liver disease

Also Published As

Publication number Publication date
TW202337470A (zh) 2023-10-01
EP4408428A1 (en) 2024-08-07
CN118251221A (zh) 2024-06-25
US20260069598A1 (en) 2026-03-12
IL311670A (en) 2024-05-01
WO2023049491A1 (en) 2023-03-30
AR127165A1 (es) 2023-12-27
CA3233319A1 (en) 2023-03-30
AU2022348966A1 (en) 2024-04-11
KR20240073926A (ko) 2024-05-27
EP4578499A3 (en) 2025-09-17
CL2024000886A1 (es) 2024-08-30
EP4578499A2 (en) 2025-07-02
MX2024003967A (es) 2024-06-03
US20240408102A1 (en) 2024-12-12

Similar Documents

Publication Publication Date Title
US11400072B2 (en) Methods for the treatment of nonalcoholic fatty liver disease and/or lipodystrophy
JP2024536126A (ja) 肝体積を減少させるためのレスメチロム
EP3435996B1 (en) Elafibranor for use in the treatment of primary biliary cholangitis
JP6941109B2 (ja) Ｆｘｒアゴニストを使用するための方法
JP6986022B2 (ja) Ｆｘｒアゴニストを使用するための方法
CN105764498A (zh) 纯合家族型高胆固醇血症的治疗
US11331292B2 (en) Methods of treatment of cholestatic diseases
KR20220041104A (ko) Fxr 작용제를 포함하는 치료
CN101646686A (zh) 铁过剩症的预防或治疗剂
CN115364224B (zh) Glut1抑制剂作为线粒体自噬诱导剂的用途
US20240423992A1 (en) Biomarkers for treating liver disorders with thr-b agonists and related uses
HK40128789A (en) Resmetirom for reducing liver volume
TW202245775A (zh) 用於治療肝病症或脂質病症之瑞舒伐他汀（Ｒｏｓｕｖａｓｔａｔｉｎ）和瑞司美替隆（Ｒｅｓｍｅｔｉｒｏｍ）的治療組合
JP2023544220A (ja) 肝疾患を治療するための併用療法
RU2850978C1 (ru) Применение агониста рецептора сфингозин-1-фосфата
HK40096516A (en) Methods of treatment of cholestatic diseases
WO2025224044A1 (en) Methods of treatment of primary biliary cholangitis
TW202539665A (zh) Fgfr4抑制劑與ppar促效劑之組合
WO2019233473A1 (zh) 脂肪性肝病及其相关疾病的预防和治疗性药物

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250929

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20250929